Bruno Vision Care Gets FDA Approval for Deseyne® Contact Lens with FusionTechnology™
Bruno Vision Care LLC, an innovative leader in eye care technology, has achieved a major milestone with the FDA’s approval of its Deseyne® (vifilcon C) daily disposable contact lens featuring the company’s groundbreaking FusionTechnology™. This approval allows Bruno Vision Care to bring this cutting-edge product to the U.S. market, setting a new standard in contact lens technology.
Deseyne® lenses represent a significant leap in the field of vision care, combining two patented innovations: the lens material, known as vifilcon C, and the proprietary FusionTechnology™ delivery system. The unique vifilcon C material is a highly enriched hydrogel that helps deliver long-lasting comfort to wearers. During the manufacturing process, bioactive substances, referred to as Lachryceuticals®, including amino acids, vitamins, and polysaccharides, are embedded into the lens matrix. Through a patented controlled release mechanism, these substances are gradually released into the eye’s anterior segment, ensuring their bioavailability throughout the day for continuous comfort.
FusionTechnology™ is a breakthrough in contact lens design. It merges hyaluronic acid (HA) with Tamarind Seed Polysaccharides (TSP®) to form a natural bio-copolymer that mimics the composition of natural tears. This bio-copolymer is activated by factors like body temperature, blinking, and eyelid pressure, ensuring that the Lachryceuticals® blend seamlessly with the natural tear film. This innovative technology improves eye hydration, comfort, and stability, offering an enhanced wearing experience.
Eddie Catalfamo, CEO of Bruno Vision Care, expressed his enthusiasm about the approval, stating, “Deseyne® isn’t just another contact lens; it defines an entirely new category. With our FusionTechnology™ delivery system and vifilcon C material, we are setting a new standard in vision health. This technology makes wearing contact lenses more comfortable, improves hydration and clarity of vision, and simplifies fitting for eye care professionals. It’s a breakthrough that’s set to change the industry and bring a game-changing solution to consumers.”
Bruno Vision Care is backed by a highly experienced management team and medical advisory board, and the company plans to launch the Deseyne® lenses to U.S. consumers in the fourth quarter of 2025.
Dr. Paul Karpecki, O.D., a respected expert in dry eye disease with over 25 years of experience, praised the Deseyne® lens. He said, “There is nothing like the Deseyne® lens with FusionTechnology™ on the market today. The lens’s unique design releases Lachryceuticals®—key components of the tear film—continuously throughout the day, ensuring optimal hydration and comfort. Dryness is the leading cause of performance issues for contact lens wearers and is the primary reason why 18% of wearers stop using lenses each year. This lens provides unmatched comfort and promotes ocular health, setting a new standard in the industry.”
Catalfamo further emphasized the importance of FDA approval for the company’s growth. “This approval is a major milestone for Bruno Vision Care,” he said. “We aim to bring radical innovation to the global soft contact lens market, which has seen little advancement in recent years. With an aging population, increased disposable income, and rising instances of distance vision impairments, we believe Deseyne® will play a critical role in reshaping the future of eye health.”
Bruno Vision Care’s breakthrough technology is poised to make a significant impact in the contact lens industry, capitalizing on structural trends like the increasing global prevalence of vision issues. The company sees Deseyne® as the first step in a broader effort to deliver innovative vision solutions to consumers worldwide.
Catalfamo also expressed gratitude for the hard work that led to the FDA approval. “Bringing this breakthrough product to the U.S. market has been our mission for many years,” he stated. “We could not have achieved this without the dedication of our U.S. and Italian teams. I want to extend my heartfelt thanks to Vincenzo Bruno and his family, our General Manager, Daniele Bazzocchi, for their exceptional technical expertise, and the world-class leaders who guided us throughout the FDA clearance process.”
About Bruno Vision Care LLC
Bruno Vision Care LLC is a pioneering leader in vision health technology, dedicated to transforming the lives and lifestyles of patients worldwide. Founded in 2019 as a subsidiary of Bruno Farmaceutici, Italy’s third-largest pharmaceutical company, Bruno Vision Care is rooted in a legacy of excellence in patient care across various medical fields. The company’s leadership team brings over 200 years of combined experience in advancing vision science and is committed to research and innovation aimed at eliminating myopia and other ocular co-morbidities that affect millions of people globally.
